Department of Surgery, University of Alberta Hospital, Edmonton, AB, Canada.
Ann Surg Oncol. 2023 Dec;30(13):8381-8388. doi: 10.1245/s10434-023-14143-6. Epub 2023 Aug 24.
Preserving the nipple-areolar complex (NAC) in breast cancer surgery improves patient satisfaction and quality of life. The oncologic safety of NSM in tumors < 2 cm from the nipple remains in question. We conducted a systematic review to determine whether TND < 2 cm was associated with increased risk of LRR in patients undergoing NSM.
We included studies of invasive or in situ breast cancer < 2 cm from NAC undergoing NSM which reported LRR rates. LRR rates were stratified by TND and culminated across studies. Cohort study quality was assessed using Newcastle-Ottawa Criteria. Meta-analysis was not possible due to heterogeneity in reporting survival outcomes.
We identified seven retrospective cohort studies with 2295 patients and 18 case series with 3507 patients. Direct tumor involvement of NAC was considered an absolute contraindication to NSM in all studies. In cohort studies, median follow-up was 31-112 (range 14-204) months. Cohorts with TND < 2 cm did not have a significantly higher rate of LRR. Amongst case series, 275 patients had TND < 2 cm. Combined LRR in case series was 2.6%, with median follow-up 10.4-71 (range 0-158) months.
Our systematic review did not identify TND < 2 cm as a significant risk factor for LRR. NSM appears oncologically safe in select patients with TND < 2 cm. Given the improved quality of life associated with NSM compared to skin-sparing mastectomy, we suggest NSM as the procedure of choice in appropriately selected patients.
在乳腺癌手术中保留乳头乳晕复合体(NAC)可以提高患者的满意度和生活质量。肿瘤距乳头<2cm 行保留乳头乳晕的乳房切除术(NSM)的肿瘤学安全性仍存在争议。我们进行了一项系统评价,以确定 TND<2cm 是否与接受 NSM 的患者局部区域复发(LRR)的风险增加有关。
我们纳入了研究浸润性或原位乳腺癌距 NAC<2cm 行 NSM 并报告 LRR 率的研究。根据 TND 分层 LRR 率,并在研究间汇总。使用纽卡斯尔-渥太华量表评估队列研究的质量。由于报告生存结局的异质性,无法进行荟萃分析。
我们确定了 7 项回顾性队列研究,共纳入 2295 例患者和 18 项病例系列研究,共纳入 3507 例患者。所有研究均认为直接侵犯 NAC 是行 NSM 的绝对禁忌证。在队列研究中,中位随访时间为 31-112 个月(范围 14-204 个月)。TND<2cm 的队列 LRR 率无显著升高。病例系列中,275 例患者 TND<2cm。病例系列的 LRR 率为 2.6%,中位随访时间为 10.4-71 个月(范围 0-158 个月)。
我们的系统评价并未发现 TND<2cm 是 LRR 的显著危险因素。在选择的 TND<2cm 的患者中,NSM 似乎具有肿瘤学安全性。鉴于 NSM 与保留皮肤的乳房切除术相比可提高生活质量,我们建议在适当选择的患者中选择 NSM 作为首选术式。